Zacks Investment Research downgraded Reata Pharmaceuticals Inc (NASDAQ:RETA) to Hold in a report released today.
- Updated: September 20, 2016
Displaying a price of $28.70, Reata Pharmaceuticals Inc (NASDAQ:RETA) traded 5.16% lower on the day. The last stock close is up 49.00% relative to the two hundred day average, compared to the S&P 500 Index which has decreased -0.01% over the same time. Reata Pharmaceuticals Inc has recorded a 50-day moving average of $19.96 and 200-day moving average of $19.13. 89,396 shares of RETA traded hands, down from ann average trading volume of 110,469
Zacks Investment Research has downgraded Reata Pharmaceuticals Inc(NASDAQ:RETA) to Hold in a report released 9/20/2016.
Previously on Saturday August 27 2016, Zacks Investment Research released a statement for Reata Pharmaceuticals Inc(NASDAQ:RETA) bumped the target price from $0.00 to $22.00 that suggested an upside of 0.15%.
With a market cap of $0.0, Reata Pharmaceuticals Inc has a one-year low of $11.03 and a 52 week high of $32.22 with a PE ratio of 0.
Brief Synopsis On Reata Pharmaceuticals Inc (NASDAQ:RETA)
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules called antioxidant inflammation modulators (AIMs). The Company’s Bardoxolone methyl is an AIM, which targets the bioenergetic and inflammatory components of pulmonary hypertension (PH), which can improve functional capacity in patients suffering from certain forms of this disease. The Company’s RTA 408 is a close structural analog of bardoxolone methyl that was developed to improve tissue distribution, and including blood-brain barrier penetration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.